CORDA Investment Management LLC. boosted its holdings in Sanofi (NASDAQ:SNY) by 12.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 129,968 shares of the company’s stock after purchasing an additional 13,990 shares during the period. CORDA Investment Management LLC.’s holdings in Sanofi were worth $6,428,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Grandview Asset Management LLC bought a new position in Sanofi in the first quarter valued at $40,000. Cardinal Capital Management Inc. bought a new position in Sanofi in the first quarter valued at $25,000. Disciplined Investments LLC grew its position in Sanofi by 2,270.8% in the first quarter. Disciplined Investments LLC now owns 569 shares of the company’s stock valued at $28,000 after purchasing an additional 545 shares in the last quarter. Oakworth Capital Inc. acquired a new stake in Sanofi in the first quarter valued at $32,000. Finally, Key Financial Inc lifted its stake in Sanofi by 926.2% in the first quarter. Key Financial Inc now owns 667 shares of the company’s stock valued at $33,000 after acquiring an additional 602 shares during the last quarter. 7.91% of the stock is owned by institutional investors and hedge funds.
SNY has been the subject of a number of recent analyst reports. Barclays reiterated an “equal weight” rating on shares of Sanofi in a research note on Thursday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Sanofi in a research note on Friday, April 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Hold” and a consensus price target of $53.00.
Sanofi (NASDAQ:SNY) last posted its earnings results on Wednesday, April 28th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.14. The company had revenue of $8.59 billion during the quarter, compared to analysts’ expectations of $8.48 billion. Sanofi had a net margin of 17.33% and a return on equity of 24.12%. Sanofi’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.63 EPS. As a group, analysts expect that Sanofi will post 3.84 earnings per share for the current fiscal year.
The business also recently announced an annual dividend, which was paid on Wednesday, May 26th. Stockholders of record on Tuesday, May 4th were paid a dividend of $1.9061 per share. This represents a dividend yield of 3.2%. The ex-dividend date of this dividend was Monday, May 3rd. This is a boost from Sanofi’s previous annual dividend of $1.21. Sanofi’s dividend payout ratio (DPR) is currently 40.90%.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.